Premium
Mass cytometry analysis of blood immune cells from psoriasis patients on biological therapy
Author(s) -
Solberg Silje Michelsen,
Aarebrot Anders Krogh,
Sarkar Irene,
Petrovic Aleksandra,
Sandvik Lene Frøyen,
Bergum Brith,
Jonsson Roland,
Bryceson Yenan Troy,
Appel Silke
Publication year - 2021
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.202048857
Subject(s) - psoriasis , immune system , peripheral blood mononuclear cell , immunology , mass cytometry , inflammation , flow cytometry , systemic inflammation , cytotoxic t cell , disease , tumor necrosis factor alpha , biology , medicine , in vitro , phenotype , biochemistry , gene
Abstract Psoriasis is a chronic immune‐mediated skin disease accompanied by systemic inflammation and comorbidities. We analyzed peripheral blood mononuclear cells (PBMCs) in the search for immune signatures and biomarkers related to psoriasis severity and treatment effect. Thirty‐two patients with psoriasis and 10 matched healthy controls were included. PBMCs were collected before and after initiation of anti‐TNF, anti‐IL‐17 or anti‐IL‐12/23 treatment and analyzed utilizing 26‐parameter mass cytometry. The number of circulating Th17, Th22, Th9, and cytotoxic T cells were increased in severe psoriasis. Intracellular pp38 and pERK in T helper cells were associated with disease severity. Differences between responders and nonresponders regarding cell composition and intracellular signaling were identifiable already at inclusion. Biological treatment induced memory cells, restored inhibitory PD‐1 function of T cells, and reduced a potential pro‐atherogenic profile in monocytes. In conclusion, these results indicate amelioration of systemic inflammation in psoriasis after biological treatment. Such broad immune profiling may enable prospective stratification of patients regarding future treatment response. Successful early intervention may lead to a healthier trajectory with favorable implications on later comorbidities.